/a//content.14388
...Mixing, granulating, milling, molding, of components, drug product containers, formulating, lyophilizing.....whether they use terminal sterilization, three initial batches in the stability.. Sampling.....Therefore, under the Federal Food, all established standards, specifications, Drug, and..
http://www.fda.gov/cder/dmpq/fr5396.pdf (score=100)

HUMAN DRUG CGMP NOTES September 1998
...Any building or buildings used in the manufacture, processing, packing or holding of a drug.....Such an investigation may entail testing other lots to ensure the product's stability throughout the.....components, drug product containers, closures, labeling, in-process materials and drug..
http://www.fda.gov/cder/hdn/cnotes98.htm (score=42)

HUMAN DRUG CGMP NOTES June 1966
...used in the delivery of a medical drug product is considered an integral part of the drug.....Where stability testing reveals that the BPC is stable for the intended period of use, or.....84(d), Testing and approval or rejection of components, drug product containers, and..
http://www.fda.gov/cder/hdn/hdn696.htm (score=35)

HUMAN DRUG CGMP NOTES December, 1996
...Is it acceptable for a firm to use drug components, drug product containers, or drug product closures.....However, because the technology may not have been available, older applications lacking.....Is it acceptable for a firm to use drug components, drug product containers, or drug product closures..
http://www.fda.gov/cder/hdn/cnotesd6.htm (score=32)

HUMAN DRUG CGMP NOTES March 1997
...Welcome to another edition of Human Drug CGMP Notes, our periodic memo on CGMP for human.....First is the microbial specification of the finished product or the equipment surfaces.....166, Stability testing; February, 1987 "Guideline For Submitting Documentation For The..
http://www.fda.gov/cder/hdn/cnotes37.htm (score=32)

...Because a dosage form is typically a complex unit, such changes may have an impact on drug product.....82 governs the receipt and storage of untested components, drug product containers, and.....84 pertains to the testing and approval or rejection of components, drug product..
http://www.fda.gov/cber/genadmin/cgmp.txt (score=24)

Document
...Mixing, granulating, milling, molding, of components, drug product containers, formulating, lyophilizing.....whether they use terminal sterilization, three initial batches in the stability.. Sampling.....Therefore, under the Federal Food, all established standards, specifications, Drug, and..
http://www.fda.gov/cber/genadmin/cgmp.pdf (score=24)

HUMAN DRUG CGMP NOTES March 1998
...This means that even though a drug product is not sterile, a firm must follow written.....components, drug product containers, closures, in-process materials, and drug products.....For example, microbial content that adversely affects product stability, would be objectionable..
http://www.fda.gov/cder/hdn/cnotes38.htm (score=23)

PET Drug Products … Current Good Manufacturing Practice (CGMP)
...ensure that each batch of PET drug product meets its established acceptance criteria, 1201.....stability parameters include radiochemical identity and purity, appearance, pH, stabilizer.....evaluation can include testing of the material (see Section VI, Control of Components, 276..
http://www.fda.gov/cder/guidance/4259dft.pdf (score=19)

PET Drug Products - Current Good Manufacturing Practice (CGMP)
...Appropriate parameters should be evaluated to establish and document the stability of a PET drug product under.....Large PET centers that handle large numbers of components and PET drug products should.....Stability testing of the PET drug product should be performed at the highest radioactive concentration, and the whole batch..
http://www.fda.gov/cder/guidance/4259dft.htm (score=18)

MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....manufacturing, processing, packaging, controls, stability testing, or labeling operations.....recommended for inclusion in the application regarding the components, manufacturing..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=16)

HUMAN DRUG CGMP NOTES December 1998
...84, Testing and approval or rejection of components, drug product containers, and closures.....84, Testing and approval or rejection of components, drug product containers, and closures.....84(a) specifies that each lot of components, drug product containers, and closures shall be withheld from..
http://www.fda.gov/cder/hdn/cnotesd8.htm (score=44)

Microsoft Word - CNOTES vol 1 no 4 dec 93.doc
...Abbreviated New Drug Applications; testing at each stability point? Preapproval Inspection.....two areas -- their direct effect on product quality, The specifications may be stated in.....approval or rejection of components, drug .. way to avoid problems with data manipulation..
http://www.fda.gov/cder/dmpq/CNOTES%20vol%201%20no%204%20dec%2093.pdf (score=15)

GUIDE TO INSPECTIONS OF DOSAGE FORM DRUG MANUFACTURER'S - CGMPR'S
...Determine the validity, and accuracy of the firm's inventory system for drug components.....o Validation of the number of organisms used to inoculate the product, simulated product, or similar surface, to include stability.....If the product is an OTC drug which is covered by an NDA or ANDA, FDA may review, copy and verify the..
http://www.fda.gov/ora/inspect_ref/igs/dose.html (score=14)

Guidance For the Submission of Documentation for Sterilization Process
...other processes should be addressed as each applies to the drug product,sterile packaging and.....Documentation for the Stability of Human Drugs and Biologics"and to the Center for.....The sterilization and depyrogenation processes used for containers,closures, equipment..
http://www.fda.gov/cber/gdlns/sterval.pdf (score=13)

Microsoft Word - CNOTES vol 2 no 3 sep 94.doc
...the drug product, the quantities are in the parts-per-million range. This does not mean that.....basis of stability testing on the biobatch and any.. when the application is approved, the.....product, reserve samples are needed to provide..quick and specific, although less analytic..
http://www.fda.gov/cder/dmpq/CNOTES%20vol%202%20no%203%20sep%2094.pdf (score=13)

...Under the QS regulation, for a combination product with a drug constituent part, yield and stability.....125, may not need to comply with regulations related to receipt and storage of untested.....Examples include aseptic control assurance for drug and biological product constituent parts unable to..
http://www.fda.gov/cder/guidance/OCLove1dft.doc (score=13)

Current Good Manufacturing Practice for Combination Products
...Under the QS regulation, for a combination product with a drug constituent part, yield and stability.....125, may not need to comply with regulations related to receipt and storage of untested.....Examples include aseptic control assurance for drug and biological product constituent parts unable to..
http://www.fda.gov/cder/guidance/OCLove1dft.htm (score=13)

FDA Concept Paper: Drug Products That Present Demonstrable Difficulties for...
...Factors such as drug stability in the vehicle, the specific product use, and the site of.....The performance of the valve and its compatibility with other components of the drug.....Since TDS products may contain volatile components, it is critical that the stability of the volatile components be..
http://www.fda.gov/cder/fdama/difconc.htm (score=6)

Las Vegas Injury Lawyer